PARIS – August 6, 2021 – The U.S. Food and Drug Administration (FDA) has approved Nexviazyme® (avalglucosidase alfa-ngpt) for the treatment of patients one year of age and older with late-onset Pompe diseaseA form of Pompe disease that begins after infancy and usually progresses more slowly. More, a progressive and debilitating muscle disorder that impairs a person’s ability to move and breathe. NexviazymeA newer enzyme replacement therapy designed to improve delivery of the enzyme to muscle cells. More is an enzyme replacement therapy (ERT)A treatment that replaces the missing enzyme through IV infusion. More designed to specifically target the mannose-6-phosphate (M6P) receptor, the key pathway for cellular uptake of enzymeA protein that helps the body carry out chemical reactions. More replacement therapy in Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More. NexviazymeA newer enzyme replacement therapy designed to improve delivery of the enzyme to muscle cells. More has been shown in clinical trialsA research study that tests new treatments or approaches in people. More to provide patients with improvements in respiratory function and walking distance.